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Abstract
Background: Low-grade inflammation has been repeatedly associated with both excess weight and psychosis.
However, no previous studies have addressed the direct effect of body mass index (BMI) on basal serum cytokines
in individuals with first-episode psychosis (FEP).
Objectives: The aim of this study is to analyze the effect of BMI on basal serum cytokine levels in FEP patients and
control subjects, separating the total sample into two groups: normal-weight and overweight individuals.
Methods: This is a prospective and open-label study. We selected 75 FEP patients and 75 healthy controls with
similar characteristics to patients according to the following variables: sex, age, and cannabis and tobacco
consumption. Both controls and patients were separated into two groups according to their BMI: subjects with a
BMI under 25 were considered as normal weight and those with a BMI equal to or more than 25 were considered
as overweight. Serum levels of 21 cytokines/chemokines were measured at baseline using the Human High
Sensitivity T Cell Magnetic Bead Panel protocol from the Milliplex® Map Kit. We compared the basal serum levels of
the 21 cytokines between control and patient groups according to their BMI.
Results: In the normal-weight group, IL-8 was the only cytokine that was higher in patients than in the control
group (p = 0.001), whereas in the overweight group, serum levels of two pro-inflammatory cytokines (IL-6, p = 0.000;
IL-1β, p = 0.003), two chemokines (IL-8, p = 0.001; MIP-1β, p = 0.001), four Th-1 and Th-2 cytokines (IL-13, p = 0.009;
IL-2, p = 0.001; IL-7, p = 0.001; IL-12p70, p = 0.010), and one Type-3 cytokine (IL-23, p = 0.010) were higher in patients
than in controls.
Conclusions: Most differences in the basal serum cytokine levels between patients and healthy volunteers were
found in the overweight group. These findings suggest that excess weight can alter the homeostasis of the
immune system and therefore may have an additive pro-inflammatory effect on the one produced by psychosis in
the central nervous system.
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Background
Inflammation is usually a physiological response of the
organism to harmful stimuli, whether physical, chemical,
or biological. The inflammatory state that accompanies
excess weight shows a peculiar presentation, as it is not
accompanied by infection or sign of autoimmunity and
no massive tissue injury seems to occur. In fact, it is
often called “low-grade” chronic inflammation [17].
Cytokines are hormone-like proteins that enable
immune cells to communicate and play an integral role
in the initiation, perpetuation, and subsequent down-
regulation of the immune response [28]. Several studies
have found that overweight individuals (body mass index
(BMI) ≥ 25) have higher plasma levels of some pro-
inflammatory cytokines such as IL-6, TNF-α, and IL-1β
than normal-weight individuals [16, 22].
Obesity is reported in approximately 50% of patients
with schizophrenia [2, 3]. In addition, a pro-
inflammatory state has been repeatedly associated with
first-episode psychosis (FEP) [5, 11, 12, 15], especially in
women, overweight patients, and tobacco users [9, 10].
However, no previous study has addressed the direct ef-
fect of BMI on basal serum cytokines in FEP individuals.
The aim of this study is to analyze the effect of BMI
on basal serum cytokine levels in FEP patients and con-
trol subjects, separating the total sample into two
groups: normal-weight and overweight individuals. Our
hypothesis is that higher levels of inflammatory cyto-
kines will be observed in patients than in controls in the
overweight group with respect to this same comparison
in the normal-weight group.
Methods
Study setting
The data for the present study were obtained from a large
epidemiological cohort of patients who have been treated
in a longitudinal intervention program of FEP (PAFIP:
Programa de Atención a Fases Iniciales de Psicosis) con-
ducted at the University Hospital Marqués de Valdecilla in
Cantabria, Spain. The main procedures that are carried
out in this program have been described elsewhere [19].
The program was approved by the local institutional
review board, and informed consent was obtained from
patients and their families prior to inclusion.
Subjects
In June 2016, 75 patients with FEP drug-naïve, who were
previously included in PAFIP from June 2011 to May
2016, were selected to entry in this study according to the
following criteria: (1) age between 15 and 50, (2) residency
in the catchment area, (3) experiencing their first-episode
of psychosis, (4) no prior treatment with antipsychotic
medication, (5) DSM-IV criteria for brief psychotic
disorder, schizophreniform disorder, schizophrenia,
schizoaffective disorder, or psychotic disorder not other-
wise specified. Patients were excluded if they met any of
the following criteria: (1) DSM-IV criteria for drug
dependence, (2) DSM-IV criteria for mental retardation,
and (3) history of neurological disorder or brain injury.
The diagnoses were confirmed by an experienced psych-
iatrist, applying the Structured Clinical Interview for
DSM-IV (SCID-I) 6 months following the baseline visit.
Study design
This is a prospective, open-label study. We selected 75
healthy volunteers with similar characteristics to patients
according to some possible confounding variables, such
as sex, age, and both cannabis and tobacco consumption,
that might have a pro-inflammatory effect. Both controls
and patients were separated into two groups according
to their BMI: those subjects with a BMI under 25 were
considered as normal-weight and those ones with a BMI
equal or over 25 were considered as overweight. Fasting
venous blood samples were collected at baseline.
We have performed four comparisons of the basal
serum levels of the 21 cytokines between the control
group and the patient group: (1) between normal-weight
controls and normal-weight patients, (2) between over-
weight controls and overweight patients, (3) between
normal-weight controls and overweight controls, and (4)
between normal-weight patients and overweight patients.
Serum cytokine/chemokine measurement
Serum cytokine/chemokine levels and different profiles
were measured using the Human High Sensitivity T Cell
Magnetic Bead Panel protocol from the Milliplex® Map
Kit (cat. no. HSTCMAG28SPMX21, EMD Millipore,
Billerica, MA 01821, USA), following the manufacturer’s
instructions. Briefly, assay plates were washed with wash
buffer, sealed, and mixed on a plate shaker for 10 min at
room temperature. The wash buffer was decanted and
50 μL of the diluted standards, quality controls, and
serum samples were added into the appropriate wells.
After the addition of the samples or controls, the plates
were incubated overnight at 4 °C on a plate shaker with
fluorescently labeled capture antibody-coated beads.
After overnight incubation with capture antibodies to
detect Fractalkine, GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-
5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-
21, IL-23, ITAC, MIP-1α, MIP-1β, MIP-3α, and TNF-α,
well content was removed and washed using a handheld
magnet. Then, 50 μL of biotinylated detection antibodies
were added into each well and incubated for 1 h at room
temperature while shaking. Following, without removing
well content, 50 μL of streptavidin-phycoerythrin was
added into each well. After incubation for 30 min at
room temperature, the samples were washed using a
handheld magnet and resuspended in sheath fluid.
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Finally, the samples were run on the Luminex 100/200
and the data were collected using the Luminex
xPONENT® software (v. 3.1). Analysis of the cytokine/
chemokine median fluorescence intensity (MFI) was per-
formed using the MasterPlex® QT software (v1.1). The
intra and inter-assay coefficients of variation for all cyto-
kines tested were < 5 and < 15–20%, respectively.
Statistical analysis
According to the normality Kolmogorov-Smirnov test,
all continuous variables except BMI and age were
departed from a normal distribution. Levene test shows
that age has not equality of variances. Therefore, non-
parametric tests were used for all continuous variables
except for BMI and age. Moreover, a correction for not
equality of variances was performed for the age variable.
Sociodemographic and clinical variables were analyzed
among control and patient groups using Student T test,
Wilcoxon W test or Chi-Square test as necessary.
Wilcoxon W test was used to compare the basal serum
levels of the 21 cytokines between controls and patients
in four different analyses as it was mentioned in the
study design section. Although these are considered as
planned or “a priori” contrasts, as many tests are being
conducted, the probability of making a type I error (false
positive) is increased. Keeping this in mind, we decided
to apply the Bonferroni adjustment for planned compari-
sons and lowering the threshold of statistical significance
to 0.0125 (0.05/4 = 0.0125), being 4 the number of inde-
pendent contrasts that have been conducted.
For describing the samples, means and standard devia-
tions were used in the case of continuous variables,
whereas the total number of observations and percent-
ages were used for qualitative variables. Median serum
cytokine levels and interquartile range (IQR) were repre-
sented by box plots after performing a natural logarith-
mic transformation.
STATA 15.0 was used for statistical analysis. Statistical
tests were two-tailed with a 99% confidence interval.
Results
Differences in sociodemographic and clinical variables
As shown in Table 1, there were no statistically signifi-
cant differences between healthy volunteers and patients
in terms of demographic and clinical variables (all ps >
0.1), except for BMI (t = − 4.06; p = 0.001) in the
normal-weight group, and in terms of age (t = 2.49; p =
0.017) and cannabis-use (Χ2 = 10.97; p = 0.001) in the
overweight group.
Basal serum cytokine levels: analyses stratified by BMI
Out of 75 patients, 53 (70.7%) had a BMI under 25 and
thus were considered as normal-weight individuals
(BMI mean = 20.3; sd = 2.28), whereas 22 (29.3%) were
considered as overweight individuals (BMI mean = 28.2;
sd = 2.28). Of the control subjects, 45 (60%) were ini-
tially considered as normal-weight (BMI mean = 22.0;
sd = 1.77), whereas 30 (40%) were classified as belong-
ing to the overweight group (BMI mean = 29.6;
sd = 3.83).
In comparison of the basal serum cytokine levels
between healthy volunteers and patients with normal
weight, Fig. 1 shows that IL-8 was the only cytokine that
was higher in patients than in the controls (p = 0.001).
In comparison of the basal serum cytokine levels
between healthy volunteers and patients with overweight
as shown in Fig. 2, serum levels of two pro-
inflammatory cytokines (IL-6, p = 0.000; IL-1β, p =
0.003), two chemokines (IL-8, p = 0.001; MIP-1β, p =
0.001), four Th-1 and Th-2 cytokines (IL-13, p = 0.009;
IL-2, p = 0.001; IL-7, p = 0.001; IL-12p70, p = 0.010), and
one Type-3 cytokine (IL-23, p = 0.010) were higher in
patients than in the controls. As a secondary analysis,
we have compared the basal serum cytokine levels be-
tween normal-weight and overweight individuals within
both groups of healthy volunteers and patients, as shown
in Figs. 3 and 4. No differences were found between the
normal-weight and the overweight individuals in the
control group (all ps > 0.01), whereas in the patient
group, the overweight individuals had higher levels of
several cytokines such as IL-6 (p = 0.000), IL-13 (p =
0.000), IL-2 (p = 0.002), IL-7 (p = 0.000), and MIP-1β
(0.010) than the normal-weight individuals.
Discussion
These findings support our main hypothesis that excess
weight can alter the homeostasis of the immune system
and therefore may have an additive pro-inflammatory
effect on the one produced by psychosis in the central
nervous system (CNS). As far as we know, this is the
first research that studies the direct effect of excess
weight on basal serum cytokine levels in individuals
with FEP.
In the present study, we separated the subjects into
two different groups according their BMI (Table 1). In
the normal-weight group, only the IL-8 (chemokine) was
higher in patients than in healthy volunteers, whereas in
the overweight group, we found more differences, as
expected: patients had higher levels than the control
subjects of two pro-inflammatory cytokines (IL-6 and
IL-1β), two chemokines (IL-8, MIP-1β), four Th-1 and
Th-2 cytokines (IL-13, IL-2, IL-7, IL-12p70), as well as
one Type-3 cytokine (IL-23) (Figs. 1 and 2). IL-8 seems
to be the chemokine more related to psychosis and
might be considered as a probably state/trait marker of
the disease. This is supported by the fact that its levels
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are not influenced by weight (no differences were found
between overweight patients and normal-weight
patients, as shown in Fig. 4), as well as its levels are
higher in patients than in healthy volunteers in both
overweight comparison and in normal-weight compari-
son (see Figs. 1 and 2). In addition, one article by Hayes
et al. (2014) found higher IL-8 levels in the cerebrospinal
fluid (CSF) of schizophrenia patients than in healthy vol-
unteers; they concluded that the differences observed
were consistent, suggesting these may represent a trait
marker associated with psychosis. Regarding the rest of
altered cytokines between patients and controls in the
overweight group, the cytokines which are more related
to overweight are IL-6, TNF-α, and IL-1β. The fact that
these cytokines are not higher in the overweight control
group than in the normal-weight control group suggest
that excess weight in isolation, without the synergistic
pro-inflammatory effect of psychosis, might not be
enough to alter these cytokines in some cases.
Previous studies carried out in FEP either have
excluded the overweight individuals [7, 20, 23] from the
analysis or have not considered the BMI in the analysis
[6, 18] because the result was similar between patients
and controls. Regarding the two articles that did not
consider the effect of the BMI, Di Nicola et al. [6] and
Noto et al. [18] observed that IL-6, TNF-α, and IL-8
were higher in patients than in healthy volunteers. On
the other hand, regarding the three studies which
Fig. 1 Basal serum cytokine levels in the normal-weight group (BMI < 25)















N (%) n (%) n (%) n (%) n (%) Statistics
Sex (female) 76 (50.7) 23 (51.1) 31 (58.5) 13 (43.3) 9 (40.9) Χ2 = 0.53; p = 0.464a
Χ2 = 0.03 p = 0.861b
Cannabis users 51 (34.0) 12 (26.7) 24 (45.9) 14 (46.7) 1 (4.6) Χ2 = 3.63; p = 0.057a
Χ2 = 10.97; p = 0.001b
Tobacco usersc 76 (51.4) 22 (48.9) 27 (51.9) 19 (63.3) 8 (38.1) Χ2 = 0.09; p = 0.766a
Χ2 = 3.16; p = 0.076b
Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) Statistics
Age at onset (years) 29.2 (7.15) 28.2 (6.09) 27.7 (7.33) 29.6 (6.53) 34.5 (7.46) t = − 0.33; p = 0.739a
t = 2.49; p = 0.017b
BMI at baseline (kg/m2) 23.8 (4.59) 22.0 (1.77) 20.3 (2.28) 29.6 (3.83) 28.2 (2.28) t = − 4.06; p = 0.000a
t = − 1.50; p = 0.139b
aComparison between patients and healthy volunteers in the normal-weight group
bComparison between patients and healthy volunteers in the overweight group
cn = 148
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excluded overweight individuals from the analysis, Ding
et al. [7] found that IL-6 and IL-17 were increased in pa-
tients when compared to controls, Song et al. [23] found
that IL-6, TNF-α, and IL-1β were elevated in patients
compared to healthy volunteers, and [20] observed that
IL-6 and IL-2 were higher in patients than in controls.
We suggest three possible reasons that may explain
the discrepancies between our findings in the normal-
weight group, in which only IL-8 was increased in
patients as opposed to the control subjects, and previous
studies that excluded the overweight individuals [7, 20, 23],
where several pro-inflammatory cytokines as well as
Th-1 and Th-2 cytokines are altered. First, whereas
our study population is of Caucasian origin, the stud-
ies by Ding et al. [7] and Song et al. [23] were con-
ducted in Asian populations, so some of the
differences could be explained by genetic background.
Second, cannabis, which is known to play a role in
the homeostasis of the immune system [24], has not
been considered as a possible confounding variable in
the match of any of the three studies. Third, it is im-
portant to remark that individuals with identical BMI
may have different body compositions regarding fat
and muscle, so we cannot exclude the contribution of
Fig. 2 Basal serum cytokine levels in the overweight group (BMI≥ 25)
log-transformed data * (p<0.01); ** (p<0.001)
Fig. 3 Basal serum cytokine levels within the control group
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adipose tissue or of other lymphoid or non-lymphoid
cells to the elevated levels of pro-inflammatory
cytokines [6, 26].
Excess weight may produce a pro-inflammatory effect
when BMI is equal or over 25 [16, 22]. Thus, although
there is a statistically significant difference between BMI
of healthy volunteers and patients in the normal-weight
group (see Table 1), as BMI is under 25 in both sub-
groups, the difference observed should not assume any
effect on the cytokines studied.
In this study, the overweight controls used more can-
nabis than the overweight patients (p = 0.001), as shown
in Table 1. Cannabis may have an anti-inflammatory
effect [24] that could explain why more differences have
been found in the overweight group with regard to the
normal-weight group. Thus, we have repeated the previ-
ous analysis excluding cannabis-use individuals and
found that the results remain similar. Because the can-
nabis variable is qualitative (consumption yes/no), we
may speculate that our findings seem to support the
notion that overweight controls might consume small
amounts of cannabis and therefore it seems not to have
any anti-inflammatory effect on the cytokines studied.
Regarding the likely effect of age in our study, patients
in the overweight group are older than the controls (p =
0.017), as shown in Table 1. Álvarez-Rodríguez et al. [1]
described a positive correlation between age and some
circulating pro-inflammatory cytokines, such as TNF-α,
IL-1β, IL-6, and IL-12. However, this correlation was
observed for individuals with a mean age difference
much greater than the one observed in our sample
(25 years of age difference VS 5 years of age difference,
respectively). In addition, as shown in Fig. 2, patients in
the overweight group had higher levels of other
cytokines besides the pro-inflammatory ones that have
not been previously correlated with age, such as two
chemokines (IL-8 and MIP-1β) and also several Th-1
and Th-2 cytokines (IL-13, IL-2, and IL-7).
Three original studies [8, 13, 21] and one meta-
analysis [27] have found elevated mRNA expressions of
several pro-inflammatory cytokines and Toll-like
receptors in post-mortem brains of individuals with
schizophrenia. Moreover, as it was mentioned above,
Hayes et al. [14] found higher levels of IL-8 in the CSF
of psychosis individuals compared to healthy volunteers.
However, peripheral blood is a biological matrix not
sensitive enough to detect immune disturbances in the
CNS. Furthermore, it is possible that CNS immune
changes may be only observed after a second hit. Thus,
the inflammation induced by the overweight might be the
spark that initiates the fire and the inflammation caused
by psychosis would be the second hit [16, 22, 25]. The fact
that the largest differences in the basal cytokine levels
between patients and healthy volunteers were found in the
overweight group might be explained by the additive pro-
inflammatory effect of both excess weight and psychosis
[4, 22]. This is supported by the analyses comparing the
basal serum cytokine levels between normal-weight and
overweight individuals within the groups of healthy
volunteers and patients; Fig. 3 shows no differences in the
cytokine levels between overweight and normal-weight
healthy volunteers, whereas in Fig. 4, it is depicted that
overweight patients have higher inflammatory cytokine
and chemokine levels than the normal-weight patients.
Keeping this in mind, we suggest that cytokines are prob-
ably not the best biomarkers to detect the inflammation
log-transformed data * (p<0.01); ** (p<0.001)
Fig. 4 Basal serum cytokine levels within the patient group
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that is taking place in the CNS because they are influ-
enced by several confounding factors such as BMI, canna-
bis use, the taking of analgesics and anti-inflammatory
drugs, stress, and age.
This study has several limitations that should be
considered: (1) stress level, which is known to influence
inflammatory status, was not measured; (2) we have not
been able to gauge the possible influence of adipose tis-
sue on the pro-inflammatory cytokines; (3) we were not
able to consider the consumption of classical analgesic
or anti-inflammatory drugs as possible confounding
factors (however, it is important to remark that the
subjects from this study are young, healthy individuals
without chronic diseases or chronic treatments); and (4)
analyses were performed on peripheral blood. We
assume that these findings are an indirect reflection of
the CNS events; therefore, we would expect to find a
greater disturbance of these cytokines in the CNS.
Conclusions
We found that the most remarkable differences in the
basal serum cytokine levels between patients and healthy
volunteers were found in the overweight group. In
addition, the overweight patients had higher levels of sev-
eral inflammatory cytokines and chemokines than the
normal-weight patients, whereas no differences were
found between the normal-weight controls and the over-
weight controls. Considering these findings, we suggest
that excess weight may help to detect immune alterations
in peripheral blood that are taking place in the CNS by
psychosis, due to a possible additive pro-inflammatory ef-
fect that alters the homeostasis of the immune system.
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